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Abstract  
  
Purpose 
To assess the impact of 6% tetrastarch (hydroxyethyl starch (HES) 130/0.4 and 
130/0.42) in severe sepsis patients. The primary outcome measure was 90-day 
mortality. 
Methods 
A structured literature search to identify prospective randomized controlled trials 
(RCT) in adult patients with severe sepsis receiving 6% tetrastarch (potato or waxy 
maize origin), as part of fluid resuscitation in comparison to other non-HES fluids 
after randomisation, in the critical care setting was undertaken. A systematic review 
and meta-analysis was performed.  
Results 
Six RCTs were included (n = 3033): three from 2012 (n = 2913) had a low risk of 
bias. Median tetrastarch exposure was 37.4 ml/kg (range 30 to 43). Ninety-day 
mortality was associated with tetrastarch exposure (relative risk (RR) 1.13; 95% 
confidence interval (CI) 1.02 to 1.25; p = 0.02) compared to crystalloid. The number 
needed to harm (NNH) was 28.8 (95% CI 14.6 to 942.5). Publication bias and 
statistical heterogeneity (I2 = 0%) were not present. Tetrastarch exposure was also 
associated with renal replacement therapy (p = 0.01; NNH 15.7) and allogeneic 
transfusion support (p = 0.001; NNH 9.9). No difference between groups was 
observed for 28-day mortality, comparison with colloid as control, and for waxy 
maize derived tetrastarch, but power was lacking. Overall mortality was associated 
with tetrastarch exposure (RR 1.13; 95% CI 1.02 to 1.25; p = 0.02).  
Conclusions  
In our analysis, 6% tetrastarch as part of initial fluid resuscitation for severe sepsis 
was associated with harm, and as alternatives exist, in our view should be avoided.  
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Introduction 
Hydroxyethyl starch (HES) solutions are in widespread use worldwide as a colloid to 
maintain or achieve volume expansion, and the resuscitation of critically ill patients 
with severe sepsis a major indication.[1, 2]  
 
Specification of HES has evolved to 6% tetrastarch, launched in Germany in 1999, 
and licenced in the US in 2008. 6% tetrastarch products have an average molecular 
weight of 130 kDa (±20 kDa), and somewhat overlapping molar substitution[3] (the 
number of hydroxyethyl groups per glucose molecule) of 0.38 to 0.45 (where the term 
tetrastarch is derived), often abbreviated as 6% HES 130/0.4 or 130/0.42. Starch 
preparations of waxy maize or potato origin are available in various crystalloid carrier 
solutions. They differ in terms of C2/C6 pattern of hydroxyethylation. It is currently 
unclear if these chemical differences are of clinical significance. Despite widespread 
clinical use, the safety and efficacy of HES are controversial.[4-7] 
 
Large critical care randomised controlled trials (RCTs) in severe sepsis reporting 
harm from HES,[8, 9] concern over publication bias supporting HES,[5, 6] and 
retraction of studies, have raised safety and efficacy concerns.[4, 10-12] 6% 
tetrastarch products were studied in eleven retracted papers,[13] however, severe 
sepsis patients were not the main study population in these. A meta-analysis of 6% 
tetrastarch use in severe sepsis is lacking, and might address safety and efficacy. 
 
Meta-analyses focusing on mortality associated with 6% tetrastarch,[5, 13] and other 
HES formulations,[14, 15] in various clinical groups and settings, have failed to 
confirm adequate safety or efficacy. Most of the studies pooled were small, clinically 
and statistically heterogeneous, and were not designed to assess mortality. Their short 
follow-up (often hours to a few days) and low mortality rate means Type II error from 
low power is a major concern.[16] Variable length of follow-up may partly explain 
the high heterogeneity in overall mortality. Studies comparing 6% tetrastarch to older 
higher molecular weight HES solutions are unsatisfactory for the assessment of 
relative safety or efficacy[17-21] compared to non-HES solutions.  
 
Patients with severe sepsis have a high mortality of 24 to 39% at 28 days, and 33 to 
50% at 90 days.[22-24] Ninety-day mortality was the primary outcome in the 2012 
6S[25] and CHEST[3] trials that compared 6% tetrastarch to crystalloid control fluid. 
6S[25] (n = 798) reported harm at 90-days (p = 0.03),[25] and CHEST[3] no 
difference overall (n = 7000), or in the sepsis sub-group (n = 1937), at 28- and 90-
days. CHEST mortality rate and power were lower than 6S, and the number of 
patients with severe sepsis or septic shock was not reported. However, persistent 
separation of Kaplan-Meier survival curves occurs between 5 and 15 days.[3, 25, 26]  
 
To assess safety and efficacy, international consensus recommends 90-day mortality 
as the primary outcome measure in all sepsis studies.[27] Hence, we conducted a 
systematic review and meta-analysis to examine whether administration of 6% 
tetrastarch as compared to other non-HES fluids was associated with 90-day mortality 
in critically ill patients with severe sepsis. Other outcomes assessed were 28-day and 
overall mortality, requirement for renal replacement therapy, and allogeneic 
transfusion support.  
Materials and Methods 
Objectives 
To use the PRISMA[28] statement methodology to conduct a systematic review and 
meta-analysis of randomized clinical trials to determine whether 6% tetrastarch 
consistently differs from control non-HES fluid regimens in its effects upon mortality. 
The primary outcome measure was 90-day mortality.[27] The secondary outcome 
measure was overall mortality at final follow-up.[27] Post hoc sub-groups were 
explored for these outcome measures: by type of control fluid (colloid or crystalloid), 
tetrastarch origin (potato or waxy maize) and C2/C6 hydroxyethylation ratio (6:1 or 
9:1). Tertiary outcome measures were 28-day mortality, renal support (renal 
replacement therapy (RRT)), acute kidney injury according to creatinine-based 
RIFLE[29] categories, allogeneic transfusion support, and adverse events.  
 
Identification of studies  
A literature search of PubMed, PubMed Central, Web of Science (includes 
MEDLINE), OvidSP (includes EMBASE, Ovid MEDLINE), the Cochrane Library, 
clinicaltrials.gov, and controlled-trials.com was undertaken on the 1st of November 
2012. The terms used were “sepsis” with all of the following: “hydroxyethylstarch”, 
“hydroxyethyl starch”, “hydroxy ethyl starch”, “hydroxy ethylstarch”, “starch”, 
“130/0.4”, “tetrastarch”, “Tetraspan”, “Voluven”, “HES”. No language or date 
restriction was applied. Reference lists of evaluable studies, systematic reviews, meta-
analyses and reports were also hand searched for additional studies eligible for 
inclusion. Grey literature were also sought[30] through supplementary material 
published online, including international drug data sheets. For included studies, if 
patients were in a pre-defined sub-group we made efforts to contact the corresponding 
author for clarification and additional data. 
 
Screening of studies 
Two reviewers independently screened the initially identified studies from the search. 
Full text articles of potentially eligible studies were independently assessed against 
the eligibility criteria. For each study, data extraction and appraisal of internal validity 
was undertaken independently. Disagreements between the two reviewers were 
resolved in meetings or referred to the third reviewer for resolution. 
 
Eligibility criteria 
All of the following criteria were met for inclusion of a study: 
1. Prospective randomized clinical trial 
2. Reporting on adult human subjects (18 years or older)  
3. Critical/intensive care unit setting 
4. Trial, or pre-defined subgroup, focused on patients diagnosed with severe 
sepsis[31] present at randomisation 
5. Fluid therapy was administered for volume expansion after randomisation 
6. At least one exposure group that received 130 kDa 6% tetrastarch (in any 
carrier or of any origin or of any molar substitution or hydroxyethylation) after 
randomisation 
7. At least one control exposure group that received any non-HES fluid 
(crystalloid or colloid) after randomisation 
8. Reporting of a mortality outcome at 90-days, and/or 28-days, and/or another 
follow-up time point. 
9. At least one death in each of the 6% tetrastarch and control exposure groups 
(to facilitate meta-analysis). 
 
Data extraction  
Data from the longest complete follow-up was defined as overall mortality.[27] Data 
on the following study characteristics were collected: clinical setting, number of 
randomised patients, number of patients with severe sepsis, time of final follow-up, 
proportion of patients present at follow-up (data completeness), and primary end-
point. When mortality was reported at different follow-up intervals, data from the 
longest complete follow-up was used along with 28- and 90-day values.[27] All cause 
death in the control group was used as a measure of baseline mortality for each study. 
Sufficient data were collected to calculate observed study power[32-34] for the end-
point of mortality at final follow-up. 
 
The overall sepsis management protocol used was recorded. Details of baseline 
patient characteristics by group were also collected: age, sex, marker of disease 
severity (Acute Physiology and Chronic Health Evaluation II (APACHE II))[35] or 
organ dysfunction (sequential organ failure assessment (SOFA)),[36] and an estimate 
of septic shock (and/or use of vasopressors or inotropes).[27, 31] 
 
Data related to study fluid exposure were collected. This included days of trial fluid 
exposure, type of trial and control group fluid, prescribed fluid dose, and actual dose 
administered (total and daily trial fluid). Details of RRT support, RIFLE criteria[29] 
components, and allogeneic transfusion support by group were also collected. 
Information on reported adverse effects, such as pruritus was also sought. Values 
were calculated if not stated, and means or medians were accepted if reported. Infused 
doses of intervention and control fluids were extracted and normalized for a 70 kg 
person in ml/kg or ml/kg/day to allow comparison between studies. 
 
For studies with greater than one control exposure group, a single non-HES 
containing comparator was selected, with preference given to crystalloid, then colloid. 
The remaining control groups were not included in the pooled analysis. Retracted 
studies were excluded.[10, 11, 13]  
 
Quality assessment 
Study quality and bias risk of individual studies and across studies was assessed with 
the Cochrane collaboration tool.[37] Studies at high risk of bias were included unless 
full evaluation was not possible for any reason, including lack of an English translated 
version of a publication. A funnel plot was used to determine publication bias. 
 
Statistical analysis 
The primary outcome summary measure was relative risk (RR) of 90-day mortality. 
The secondary outcome measure was RR of overall mortality. Post hoc sub-groups 
were 6% tetrastarch hydroxyethylation ratio/starch origin and type of control fluid for 
these two outcome measures. Tertiary outcome measures were RR of 28-day 
mortality, RR of RRT, RR of allogeneic transfusion, and RR of pruritus.  
 
The RR of death for 6% tetrastarch compared to control fluid was calculated for each 
included study. Then pooled RR of studies and their 95% confidence intervals (CI) 
were calculated. Statistical heterogeneity was assessed using the Chi2 test (Cochran 
Q) and I2 statistic.[38] I2 values of 25%, 50%, and 75% were considered as low, 
moderate, and high.[39] A random effects model was used in the presence of 
statistical heterogeneity (Tau2 was reported as another measure of statistical 
heterogeneity; >1 suggests heterogeneity). Clinical heterogeneity (judged by two 
reviewers) could not be excluded, so the more conservative random effects model[40] 
(Mantel-Haenszel method) was used.  
 
Sensitivity analysis was performed by excluding studies with a high risk of bias, and 
also by using a fixed effects model. Sensitivity analyses with or without CHEST data 
was performed where appropriate because it was unclear if the reported pre-defined 
sepsis group represented only patients with severe sepsis. Studies in Forest plots were 
presented sorted by effect size. RevMan version 5.1.7 (Java 6), build 04/06/12 for 
Mac was used for analysis. Observed or post hoc power (at 95% CI without continuity 
correction) calculations were performed with OpenEpi version 2.3, May 2009. 
Number needed to harm (NNH) or treat was calculated as the reciprocal of the 
absolute risk reduction with 95% CIs, if it was statistically significant, with an online 
calculator (clinicalevidence.bmj.com). Simple calculations, including means and 
medians were derived with Microsoft Excel for Mac version 14.2.4. 
Results 
Literature search and study selection 
Figure 1 outlines a PRISMA[28] flow diagram illustrating the results of the literature 
search. Six RCTs[3, 25, 26, 41-43] published between July 2006 and October 2012 
met the eligibility criteria and were included in this meta-analysis. They described 
adults suffering from severe sepsis in the critical care setting, and reported overall 
mortality in patients exposed to 6% tetrastarch and a non-HES control fluid after 
randomisation for volume resuscitation. Four reports[44-47] were excluded because 
of inadequate information or an English translation was not available for full 
appraisal. Their abstracts did not suggest that they reported our primary outcome 
measure of 90-day mortality. They were also not included by previous reviewers in 
their meta-analyses.[5, 13]   
 
Study quality and bias 
Assessment of within study bias (internal validity) is summarised in Figure 1 (online 
supplement). The three trials reporting 90-day mortality were of good quality and had 
low risk of bias. The 6S[25] and CHEST[3] trials were specifically designed to assess 
90-day mortality (Table 1). The three[41-43] older smaller trials reporting mortality at 
other time points had risk of performance and detection bias, two had risk of selection 
bias[42, 43], one had risk of attrition bias,[41] while another had risk of reporting 
bias.[42] They were not designed to assess mortality, and the possibility of 
ascertainment bias could not be dismissed. Furthermore, information from other 
sources[14, 48] was required because of missing data. 
 The assessment of bias risk across studies (external validity) is shown in Figure 2 
(online supplement). Overall risk of bias for the studies reporting our primary 
endpoint was low. The risk of selection bias was a major concern in studies not 
reporting 90-day mortality, where performance, attrition and other risks of bias were 
also evident. Figure 3 (online supplement) shows a funnel plot assessment that does 
not yield very clear evidence of publication bias relating to the six included studies. 
Trial design and clinical heterogeneity were evident mainly for studies not reporting 
90-day mortality. 
 
Description of studies and patients 
The study characteristics extracted from the RCTs included are outlined in Table 1. 
Four[3, 25, 26, 43] of the six were multicentre, and randomised 3033 patients in 
critical/intensive care units across Europe, Australasia and South America. Five trials 
recruited patients with severe sepsis.[25, 26, 41-43] The largest trial[3] recruited 
sepsis patients in a pre-defined sub-group[49] but those with severe sepsis or septic 
shock were not reported separately. The median sepsis study sample size was 126 
patients (range 24 to 1937). Completeness of overall mortality outcome data was 
99.3% (n = 3013). The median baseline mortality assessed in the control group was 
31.9% (range 13 to 54). The overall median observed study power for mortality was 
only 15.7% (range 6.4 to 56.5).  
 
Baseline patient characteristics are outlined in Table 1 (online supplement). The mean 
age of patients exposed to 6% tetrastarch was 63.1 years (range 43 to 66) and 65 years 
in the control groups (range 47 to 67). Male patients represented a median 64% in the 
6% tetrastarch groups (range 60 to 85) compared to 60% in the control groups (range 
55 to 87). Only one[41] of the six studies reported a SOFA or APACHE II score in 
the 6% tetrastarch group that was greater than that in the control group; it was equal 
in two studies.[3, 25] A summary measure was not possible because of varied 
reporting. The proportion of patients with septic shock or those that required 
vasopressors or inotropes (these were interchangeably reported, often as a composite 
and variably defined) in four RCTs[25, 26, 41, 43] was 86.0% (range 46 to 100) in 
6% tetrastarch groups and 87.5% in control groups, as shown in Table 1 (online 
supplement). CHEST trial[3] data for their sepsis group were not available.  
 
6% tetrastarch exposure 
Sepsis management protocols used in the RCTs and details of 6% tetrastarch product 
and crystalloid or albumin control fluid are outlined in Table 2 (online supplement). 
Patients were exposed to study fluids for a median of 3.5 days (range 1 to 5). Four 
studies[3, 25, 26, 41] reported pre-defined 6% tetrastarch dosing details. Five 
studies[3, 25, 26, 41, 43] reported a median total 6% tetrastarch volume infusion of 
2615 ml (range 1379 to 3000). The median actual 6% tetrastarch dose exposure was 
37.4 ml/kg (range 30 to 43) or 14 ml/kg/day (range 8 to 37). 
 
Primary outcome: 90-day mortality 
Three RCTs[3, 25, 50] reporting in 2012 (n = 2913) presented follow-up data to 90 
days, the primary outcome measure to assess safety and efficacy. Figure 2 shows the 
excess mortality found in patients exposed to 6% tetrastarch (RR 1.13, 95% CI 1.02 to 
1.25; p = 0.02). The NNH was 28.8 (95% CI 14.6 to 942.5). Statistical heterogeneity 
was not present (I2 = 0%; Chi2 0.81, p = 0.67; Tau2 0.00). Sensitivity analysis 
performed by removing studies with risks of bias did not change this mortality 
difference (RR 1.13, 95% CI 1.02 to 1.25; p = 0.02), nor did the use of a fixed model 
(RR 1.12, 95% CI 1.01 to 1.25; p = 0.03). Exclusion of data from CHEST did not 
alter the finding of 6% tetrastarch-associated mortality (RR 1.18, 95% CI 1.03 to 
1.35; p = 0.02), as shown in Figure 4a (online supplement). Post hoc sub-group 
analysis by control fluid type did not alter this association, as crystalloid was used for 
all three studies. Analysis by C2/6 hydroxyethylation ratio and starch origin is 
presented in Figure 4b (online supplement).  
 
Secondary outcome: overall mortality 
Overall mortality was increased in patients exposed to 6% tetrastarch (RR 1.13, 95% 
CI 1.02 to 1.25; p = 0.02). The NNH was therefore 29.2 (95% CI 14.9 to 896.7). 
Statistical heterogeneity was not present (I2 = 0%; Chi2 3.49, p = 0.62; Tau2 0.00). 
Sensitivity analysis performed by removing studies with risks of bias from the 
analysis did not significantly change the finding of 6% tetrastarch-associated 
mortality (RR 1.13, 95% CI 1.02 to 1.25; p = 0.02). Also, use of a fixed model (RR 
1.12, 95% CI 1.01 to 1.24; p = 0.03) or exclusion of the CHEST data[3] yielded the 
same outcome (RR 1.17, 95% CI 1.02 to 1.34; p = 0.02). Figure 3 show the post hoc 
sub-group analyses of overall mortality by type of control fluid received, and Figure 5 
(online supplement) by 6% tetrastarch origin/pattern of C2 to C6 hydroxyethylation, 
respectively.  
 
Tertiary outcomes 1: 28-day mortality 
In this group (n = 1049), a mortality difference between 6% tetrastarch and control 
was not detected in three trials,[25, 26, 41] as shown in Figure 4. Statistical 
heterogeneity was not present and sensitivity analysis performed by removing studies 
with risks of bias (RR 1.10, 95% CI 0.93 to 1.30; p = 0.28) or by using a fixed effects 
model (1.11, 95% CI 0.94 to 1.31; p = 0.21), did not alter the finding of possible harm 
or benefit. The CHEST trial[3] did not report 28-day mortality for their pre-defined 
sepsis group. For illustrative purposes, Figure 6 (online supplement) shows inclusion 
of CHEST[3] data (n = 6644) for enrolled patients in all subgroups, but this did not 
alter the outcome. 
 
Tertiary outcomes 2a: renal replacement therapy (RRT) support 
In two studies[25, 26] (n = 994), a median of 21.4% of patients in the 6% tetrastarch 
group (range 21.0 to 21.9) and 13.9% in the control group (range 11.5 to 16.3) 
received RRT (Table 3, online supplement). Figure 5 demonstrates that the 
requirement for RRT with 6% tetrastarch exposure was increased (RR 1.41, 95% CI 
1.08 to 1.84; p = 0.01) compared to control fluid. The NNH was 15.7 (95% CI 8.9 to 
64.4). Statistical heterogeneity was not present. Sensitivity analysis performed by 
removing studies with risks of bias did not alter this finding (RR 1.41, 95% CI 1.08 to 
1.84; p = 0.01), nor did the use of a fixed model (RR 1.42, 95% CI 1.09 to 1.85; p = 
0.01). The CHEST trial[3] reported this outcome as a composite of both sepsis and 
non-sepsis patients. For illustrative purposes, Figure 7 (online supplement) shows that 
including the CHEST[3] data (n = 6727) for enrolled patients in all subgroups did not 
alter the overall finding. 
 
Tertiary outcomes 2b: acute kidney injury severity (RIFLE criteria) 
Acute kidney injury severity defined by the RIFLE criteria for severe sepsis patients 
was reported in two studies[25, 26] using a creatinine-based score, which was thus 
used for analysis. Table 4a (online supplement) shows no difference was detected 
between groups in each RIFLE category, hence one cannot rule out the possibility of 
harm or benefit with 6% tetrastarch compared to control fluid, which was crystalloid. 
Sensitivity analysis by removing studies with a risk of bias or by using a fixed model 
did not alter this overall finding or for any of the RIFLE components. Table 4b 
(online supplement) shows for illustrative purposes the inclusion of creatinine-based 
RIFLE data from the CHEST trial[3], including both sepsis and non-sepsis patients. 
6% tetrastarch exposure was associated with RIFLE –I and –F, but not RIFLE-R and 
the two clinical outcome components –L and -E. Sensitivity analysis performed by 
removing studies with a risk of bias or by using a fixed model did not alter these 
findings. 
 
Tertiary outcomes 3: allogeneic transfusion  
The median proportion of patients that received allogeneic transfusion in the 6% 
tetrastarch group in three studies [25, 43, 50] (n = 972) was 29% (range 22 to 65) 
compared to 21% (range 18 to 54) in the control group (Table 3, online supplement). 
Figure 6 demonstrates the increased RR of allogeneic transfusion in patients exposed 
to 6% tetrastarch (RR 1.21, 95% CI 1.08 to 1.36; p = 0.001) compared to control 
fluid, which were crystalloid. The NNH was 9.9 (95% CI 6.1 to 26.1). Statistical 
heterogeneity was not present. Sensitivity analysis performed by excluding the study 
with a risk of bias[43] did not alter the conclusion (RR 1.21, 95% CI 1.08 to 1.36; p = 
0.001), nor did the use of a fixed effects model (RR 1.22, 95% CI 1.08 to 1.37; p = 
0.0009). In three RCTs[25, 26, 42] this corresponded to a median transfusion volume 
of 1340 ml (range 214 to 1500) in the 6% tetrastarch group compared to 1055 ml 
(range 165 to 1400) in the control group (Table 3, online supplement). The CHEST 
trial did not report these outcomes in their sepsis subgroup. 
 
Tertiary outcomes 4: pruritus 
Pruritus was reported in two studies[3, 26] (CHEST reported this for all randomised 
patients) and was associated with 6% tetrastarch exposure (RR 1.81, 95% CI 1.37 to 
2.38; p = <0.00001). Observed power was 99.0% and NNH was 56.1 (95% CI 38.6 to 
102.9). Statistical heterogeneity was not present (I² = 0%; Chi² = 0.64, p = 0.42; Tau² 
= 0.00). Sensitivity analysis with a fixed model did not alter this conclusion or any of 
the statistical values. Other reported adverse events were reported in included studies 
but these were not amenable to pooled summary. 
 
 
Discussion 
This meta-analysis has found that mortality in severe sepsis patients is associated with 
exposure to 6% tetrastarch products in the critical care setting (Figure 3; Figure 5 
online supplement). This excess mortality was identified at 90-days (Figure 2) - the 
primary outcome measure.[27] The point estimates are concordant and the 95% CI is 
more precise than the 6S trial[25]. The results are generalizable to critical/intensive 
care patients but may not apply to perioperative or trauma patients, where 6% 
tetrastarch is used and has also been studied. In our analysis, 6% tetrastarch is neither 
safe or efficacious: overall or at 90-days, one patient died for every 29 patients treated 
with 6% tetrastarch products instead of control fluid. 
 
This analysis was performed promptly when new data were published in 2012 adding 
significant individual study power (Table 1), and therefore updates previous meta-
analyses of 6% tetrastarch for various indications, which were unable thus far to 
address long-term safety and efficacy concerns.[5, 13, 14] The addition of the 6S[25] 
and CHEST[3] trials add 90% of the weight in this analysis that focuses on sepsis to 
address the clear knowledge gap of existing data identified by the ESICM Task Force 
committee.[7] 
 
The post hoc sub-group analysis of 6% tetrastarch origin was unsurprisingly not 
statistically significant for C2/C6 9-ratio waxy maize products, given the low power 
of 20.7% and the median baseline 90-day and overall mortality of 28.7% and 30%, 
respectively. However, generally concordant point estimates towards possible harm 
were found (Figures 4b and 5, online supplement). The 6S trial[25] was the only 6-
ratio potato-derived 6% tetrastarch study associated with harm and has already been 
published.[25] The 9-ratio product is 98% amylopectin, persists in the intravascular 
space for longer because of reduced susceptibility to plasma amylase degradation and 
has a lower viscosity compared to the 6-ratio product which is 75% amylopectin and 
25% amylose, and more prone to form inclusion complexes with several endogenous 
lipophilic molecules.[51] For both, storage in the reticulo-endothelial system, and 
eventual conversion to water and CO2 occurs. Furthermore, the mean degree of molar 
substitution is 0.42 for the potato and 0.4 for the waxy maize-derived products,[51] 
but when the latter was measured in CHEST it was 0.44 (Table 2, online 
supplement).[3] Thus, it is unclear if these chemical differences between 6% 
tetrastarches, particularly with different plasma amylase levels,[52] are clinically 
important. However, harm is associated with their exposure in severe sepsis (Figures 
2 and 3), perhaps predicted by similar degrees of tissue uptake compared to older 
higher molecular weight HES preparations.[53] 
 
Risk of bias in the large 2012 studies assessing 90-day mortality was low and study 
quality was good.  Most patients were from this group (97.6% weight), control fluid 
was crystalloid (Table 2, online supplement), and the robust pooled results were 
unaffected by sensitivity analysis (Figure 4a, online supplement). The CHEST sepsis 
sub-group was not clearly described in the original report[3] and there were some 
missing data, but this did not affect the pooled mortality, RRT and allogeneic 
transfusion outcomes in our analysis. Pruritus was assessed in all CHEST patients, as 
this is not necessarily an adverse event specific to sepsis. A detailed sepsis analysis is 
awaited from the CHEST group (J Myburgh, personal communication) but patients 
with septic shock may have been underrepresented given the low baseline mortality 
(Table 1). 6% tetrastarch-associated mortality was found in the pooled crystalloid 
sub-group (Figure 3). Ambiguity remains about relative safety in the underpowered 
albumin sub-group but the point estimates were also concordant with 6% tetrastarch-
associated harm. There were risks of bias in the three smaller and older trials (Figures 
1 and 2, online supplement). Their primary end-points were not focused on mortality, 
data were missing, and they had a very short or unclear follow-up (Table 1).  
 
Statistical heterogeneity ranged from not present to low (Figures 2, 3, 4, 5, and 6; 
Figures 4, 5, 6, 7, and Table 4, online supplement). Greater degrees of statistical 
heterogeneity have hampered the results of previous meta-analyses.[5, 13, 14] 
Clinical heterogeneity of 6% tetrastarch dosing and frequency will remain within any 
meta-analysis (Table 2, online supplement). Therefore, the more conservative random 
effects model was used, which assumes that individual studies are estimating different 
treatment effects.  
 
Pooled data published in 2012 demonstrates 6% tetrastarch exposure increases the 
requirement of RRT support (Figures 5). This was previously found for other HES 
formulations[8, 9, 12] and suspected for 6% tetrastarch.[54] The point estimates are 
concordant and the pooled CI is narrower than already reported in trials,[3, 25] 
improving precision. Sensitivity analysis did not alter this finding suggesting it is 
robust. A meta-analysis of predominantly older higher molecular weight HES 
formulations also found similar results.[55] The indication for initiating RRT might 
vary between centres and studies introducing potential risk of bias. However, this 
effect would be expected to be the same across the blinded RCT cohorts, reducing 
potential bias affecting one particular group. The total 6% tetrastarch dose exposures 
were below 50 ml/kg, and 3000 ml or less (Table 2, online supplement), thus incorrect 
use was not a major factor.[54] Some of the renal toxicity has been attributed to 43% 
tissue uptake[53] and perhaps the effects of direct urinary ultrafiltration of less than 
60 kDa molecules.[51] Overall, one patient with severe sepsis required RRT for every 
16 patients treated with 6% tetrastarch instead of (crystalloid) control fluid. 
 
Comparison of RIFLE criteria components between 6% tetrastarch and control fluid 
could not differentiate between safety and harm, partly because of low observed 
power (Table 4a, online supplement). With inclusion of septic and non-septic patients 
enrolled in to CHEST, the more severe RIFLE-I and –F acute kidney injury grades 
were associated with 6% tetrastarch exposure (Table 4b, online supplement). 
However, no firm conclusions can be drawn from this.  
 
6% tetrastarch exposure was associated with allogeneic transfusion (Figure 6), and 
with a larger volume (Table 3, online supplement). The point estimates are 
concordant across all studies and the outcome withstands sensitivity analysis. This 
finding is consistent with non-significantly increased severe bleeding (p = 0.09) and 
significantly increased overall bleeding (p = 0.003) in the 6S study[25] but without 
major coagulation profile disturbance or blood loss in the smaller CRYSTMAS 
trial.[26] Anaemia from haemodilution,[56] reduced platelet function and clot 
strength, effects on von Willebrand factor, and on factor XIII might explain a normal 
coagulation screen in the presence of bleeding with HES exposure.[57-61] Moreover, 
effects on erythropoiesis from tissue uptake[53, 62, 63] in the bone marrow[64] of 
septic patients have not been adequately assessed, but lysosomal storage and toxicity 
might contribute. Hence this observation requires further investigation. A transfusion 
protocol was not pre-defined thus risk of bias is possible. However, the blinding of 
fluids and all personnel would likely reduce the effect of variations across the RCT 
groups, reducing the risk of imbalance. Patient characteristics were similar between 
groups, including those with septic shock (Table 1, online supplement).  
 
The open-label CRISTAL study (Colloids Compared to Crystalloids in Fluid 
Resuscitation of Critically Ill Patients: A Multinational Randomised Controlled Trial; 
ClinicalTrials.gov; NCT00318942) will report 28-day mortality as primary, and 90-
day mortality as secondary endpoints. The results might be informative as a 
sufficiently powered large RCT is often recommended to confirm meta-analysis 
findings. The open-label Impact of Early Goal-directed Fluid Therapy in Septic 
Patients Undergoing Emergency Surgery trial (ClinicalTrials.gov; identifier: 
NCT01654003) will close in December 2013. It will report 28-day mortality in 
approximately 250 patients. The results of the single centre blinded BaSES RCT (n = 
240) (ClinicalTrials.gov; identifier: NCT00273728), which completed in May 2011, 
are awaited. 
 
The major strength of this study has been to improve power sufficiently to investigate 
the safety and efficacy of 6% tetrastarch products in a defined severe sepsis 
population using the recommended outcome measure of 90-day mortality.[27] A 
major limitation has been the inability to assess definitively some tertiary outcomes, 
partly due to inadequate power, and partly because of inconsistent or inadequate 
reporting of data. Studies at high risk of bias were included but their impact on the 
primary outcome was minimal, confirmed by subsequent sensitivity analysis with 
these studies removed. We tested the impact of the available CHEST data but this did 
not affect our primary and secondary mortality outcomes.  
Summary 
Studies reporting 90-day mortality were of good quality. Overall and 90-day mortality 
was significantly higher in severe sepsis patients receiving 6% tetrastarch 130 kDa 
solutions as part of initial fluid resuscitation. On the basis of our meta-analysis of 
currently available data, in our view the use of 6% tetrastarch for volume resuscitation 
in severe sepsis cannot be recommended because of an association with harm, 
particularly as alternative fluids are available. 
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Figure 1. A PRISMA (Preferred Reporting Items for Systematic reviews and Meta-
Analyses)[28] flow diagram detailing the search, identification, screening and 
inclusion of RCTs assessed in this systematic review and meta-analysis. 
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Figure 2. Forest plot assessing the RR of mortality at 90-days, the primary outcome 
measure for safety and efficacy. The observed overall power was 52.4%. 
 
 
 
 
 
Figure 3. Forest plot assessing the RR of overall mortality, the secondary outcome 
measure, assessed at last follow-up. Observed power was 52.6%. Post hoc sub-groups 
of control group fluid type are shown. The observed power in the crystalloid control 
sub-group was 46.6% and median baseline mortality was 38.4% (range 23.7 to 53.8). 
In the colloid sub-group these were 18.6% and 21.7% respectively (Table 1). 
 
 
 
 
 
Figure 4. Forest plot assessing the RR of mortality at 28-days, a tertiary outcome 
measure. The observed power was 24.1%. 
 
 
 
 
 
  
Figure 5. Forest plot assessing the RR of RRT support, a tertiary outcome measure. 
The observed power was 73.4%. 
 
 
 
 
 
Figure 6. Forest plot assessing the RR of allogeneic transfusion support, a tertiary 
outcome measure. The observed power was 88.4%. 
 
 
 
 
 
 
 
 
 
Table 1. Characteristics of included critical care studies. The clinical setting, country 
and centres are presented with the diagnosis of recruited patients. The total numbers 
of patients randomised is presented, with baseline (control group) mortality and final 
follow-up. Data completeness for the outcome of mortality, along with observed 
power (at 95% CI) for the end-point of mortality at final follow-up, are presented. 
Each study end-point is also described. 
 
RCT Centre(s) Country / 
countries 
Clinical 
setting 
Diagnosis Patients Baseline 
mortality 
(%) 
Final 
follow-up 
(days) 
Patient 
follow-up 
(%) 
Observed 
power 
(%) 
Primary 
endpoint 
Dolecek et al. 
2009[41] 
1 Czech 
Republic 
Critical 
care 
Severe 
sepsis 
56 13.3 28 100.0 15.4 Extravascular 
lung water 
Dubin et al. 
2010[43] 
2 Argentina, 
Amsterdam 
Critical 
care 
Severe 
sepsis 
24 53.8 1?  100.0 25.1 Sublingual 
mucosa 
microcirculation 
imaging 
parameters 
CRYSTMAS 
trial 2012[26] 
24 France, 
Germany 
Critical 
Care 
Severe 
sepsis 
196 33.7 90 99.0 15.9 Efficacy of initial 
hemodynamic 
stabilization 
CHEST trial 
2012[3] 
32 Australia, 
New 
Zealand 
Critical 
Care 
Various 
(sepsis)+ 
7000 
(1937)§ 
23.7 90 99.2§ 13.7 All cause 
mortality at 90 
days 
Palumbo et 
al. 2006[42, 
48] 
1 Italy Critical 
care 
Severe 
sepsis 
20 30.0 5? 100.0 6.4 Unclear 
6S trial 
2012[25] 
26 Denmark, 
Norway, 
Finland, 
Iceland 
Critical 
Care 
Severe 
sepsis 
800 43.0 90 99.8 56.5 All cause 
mortality (or end-
stage kidney 
failure (dialysis 
dependence) at 90 
days 
 
+Sepsis was a pre-defined subgroup; §sepsis; ?uncertainty regarding time of mortality 
reporting. 
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Tables and figures 
 
Figure 1. Risk of bias summary displaying review authors' judgements about each 
risk of bias item for each included study, alphabetically listed. 
 
  
 
Figure 2. Risk of bias summary displaying review authors' judgements about each 
risk of bias item across all the included studies. 
 
 
 
Figure 3. Funnel plot assessment for publication bias, with 95% CI lines. 
 
 
 
Figure 4a. Forrest plot assessing the RR of mortality at 90-days, the primary outcome 
measure for safety and efficacy, with exclusion of CHEST trial data for sensitivity 
analysis. The observed overall power was 63.5%. 
 
 
 
 
 
Figure 4b. Forrest plot assessing the RR of mortality at 90-days, the primary outcome 
measure for safety and efficacy. The observed overall power was 52.4%. Sub-groups 
of 6% tetrastarch origin and C2/C6 hydroxyethylation ratio are shown. The observed 
power of the waxy-maize 6% tetrastarch sub-group was 20.7%, and median baseline 
mortality 28.7% (range 23.7 to 33.7). Table 1 outlines these parameters for the 6S 
study. 
 
 	  	   	  
Figure 5. Forrest plot assessing the RR of overall mortality, the secondary outcome 
measure, assessed at last follow-up. Observed power was 52.6%. Post hoc sub-groups 
of 6% tetrastarch origin and C2/C6 hydroxyethylation ratio are shown. The observed 
power of the waxy-maize 6% tetrastarch sub-group was 20.7%, and median baseline 
mortality 30% (range 13.3 to 53.8). Table 1 outlines these parameters for the 6S 
study. 
 
 	  	   	  
Figure 6. Forrest plot assessing the RR of mortality at 28-days, a tertiary outcome 
measure. CHEST trial data relates to all patients enrolled in to the sepsis and non-
sepsis groups, thus is included for illustrative purposes. The observed power was 
26.4%. 
 
 
 
  
Figure 7. Forrest plot assessing the RR of RRT support, a tertiary outcome measure. 
CHEST trial data relates all patients enrolled in to sepsis and non-sepsis groups, thus 
is included for illustrative purposes. The observed power was 86.3%. 
 
 
 
Table 1. Baseline patient characteristics. For each study the severe sepsis 
management protocol or principles are outlined along with age, sex, a marker of 
disease severity (APACHE II)[35] or organ dysfunction (SOFA),[36] and an 
indication of septic shock. 
 
 
$Mean; £median; §APACHE II score; |SOFA score; @standard deviation; &range; 
^interquartile range; EGDT (early goal-directed therapy);[65] +severe sepsis data were 
not reported thus overall values are presented for all randomised patients; ?not 
reported or unclear. 
 
  6% tetrastarch Control fluid 
RCT Management 
protocol 
Age  Male 
Sex (%) 
SOFA or 
APACHE II  
Shock or 
vasopressor 
(%) 
Age  Male 
Sex 
(%) 
SOFA or 
APACHE 
II 
Shock or 
vasopressor 
(%) 
Dolecek et 
al. 2009[41] 
Surviving 
Sepsis 
guidelines[31] 
43£ (23–
67)& 
84.6 8.8$| (3)@ 65.4 47£ (19–
81)& 
86.7 8$| (2)@ 60.0 
Dubin et al. 
2010[43] 
EGDT 
principles 
62$ (21)@ 67 8.1$| (2.5)@ 100.0 65$ (12)@ 55 8.9$| (3.6)@ 100.0 
CRYSTMAS 
trial 
2012[26] 
EGDT 
principles 
65.8$ 
(15.4)@ 
64 7.9$| (?)@ 88.0 65.9$ 
(14.7)@ 
59 9.1$| (?)@ 90.6 
CHEST trial 
2012[3]+ 
Clinician 
discretion 
63.1$ 
(17)@ 
60.5 17£§ (12–
23)^ 
45.6  62.9$ 
(16.9)@ 
60.3 17£§ (12–
23)^ 
46.1 
Palumbo et 
al. 2006[42] 
Unclear ? ? 18.5$§ (3)@ ? ? ? 19.7$§ 
(2.7)@ 
? 
6S trial 
2012[25] 
Clinician 
discretion 
66£ (56–
75)^ 
60.0 7£| (5–9)^ 84.4 67£ (56–
76)^ 
61 7£| (5–9)^ 84.3 
  
Table 2. Characteristics of both intervention and control group fluid exposures. The 
total days of study fluid exposure are outlined along with pre-defined doses for 6% 
tetrastarch and control fluid. The calculated actual fluid exposure volume and dose 
received are also presented. 
 
  6% tetrastarch Control fluid 
RCT Days 
of 
expos
ure 
HES 130 kDa 
(molar 
substitution) 
Dose 
(ml/kg
/day) 
Total 
infused 
(ml) 
Total dose 
received 
(ml/kg) 
Dose 
received 
(ml/kg/day) 
Control 
fluid 
Dose 
(ml/kg/
day) 
Total 
infused 
(ml) 
Total dose 
received 
(ml/kg) 
Dose 
received 
(ml/kg/day) 
Dolecek 
et al. 
2009[41] 
3 Voluven 
(0.4) 
14.3 3000 42.9 14.3 20% 
albumin  
2.9  600 9 2.9 
Dubin et 
al. 
2010[43] 
1 Voluven 
(0.4) 
Undef
ined§ 
2610$ 37.2 37.2 0.9% 
saline  
Undefi
ned§ 
6254$ 89.3 89.3 
CRYST
MAS 
trial 
2012[26] 
4 Voluven 
(0.4) 
37.5| 2615$ 37.4 9.4 0.9% 
saline  
37.5| 2788$ 39.8 10.0 
CHEST 
trial 
2012[3] + 
4 Voluven 
(0.4 or 0.44)* 
50.0 2104$+ 30.1+ 7.5+ 0.9% 
saline  
50 2464$+ 35.2+ 8.8+ 
Palumbo 
et al. 
2006[42] 
5? Voluven 
(0.4) 
? ? ? ? 20% 
albumin  
? ? ? ? 
6S trial 
2012[25] 
 
3 Tetraspan 
(0.42) 
33.0 3000£ 42.9 14.3 Ringer's 
acetate 
33 3000£ 42.9 14.3 
 
$Mean; £median; §dose according to clinical response; |50 on day 1, 25 on days 2 to 4. 
+sepsis data were not reported thus overall values are presented for all randomised 
patients. ?not reported or unclear. *Independent analysis of a random sample of 
CHEST study fluids reported a mean degree of molar substitution of 0.44.[3] 
Tetrastarch fluid origin: Tetraspan is potato- and Voluven is waxy maize-derived. 
 
Table 3. Characteristics of RRT and allogeneic transfusion support. The proportion of 
patients that required renal and transfusion support in the intervention and the control 
groups are outlined. The total volumes of allogeneic transfusion received during study 
fluid intervention are also presented. 
 
 6% tetrastarch Control fluid 
RCT RRT 
(%) 
Transfusion 
(%) 
Transfusion (ml) RRT (%) Transfusion 
(%) 
Transfusion (ml) 
Dolecek et al. 
2009[41] 
? ? ? ? ? ? 
Dubin et al. 2010[43] ? 22.2 ? ? 18.2 ? 
CRYSTMAS trial 
2012[26, 50] 
21.0 29.0 214$§ (358)@ (0–
1394)& 
11.4 20.8 165$§ (354)@ (0–
1661)& 
CHEST trial 2012[3] 
+ 
7.0 ? 312$ (1000)@| 5.8 ? 240$ (760)@| 
Palumbo et al. 
2006[42] 
? ? 1500$§ (750)@| ? ? 1400$§ (650)@| 
6S trial 2012[25] 21.9 64.6 1340£ (566–
2700)^ 
16.3 53.7 1055£ (600–2755)^ 
 
$Mean; £median; @standard deviation; &range; ^interquartile range; §packed red cells 
alone; |mean and standard deviation daily values multiplied by days of trial fluid 
intervention (Table 3); +sepsis data were not reported thus overall values are 
presented for all randomised patients; ?not reported or unclear. 
 
Table 4a. Meta-analysis (random effects model) characteristics of acute kidney injury 
severity and clinical outcome as defined by the RIFLE criteria.[29] Assessment was 
based on creatinine alone. The observed power (at 95% CI) for each component was 
calculated. 
 
RIFLE 
criteria 
Effect size measure Statistical heterogeneity Power 
RR 95% CI p I2 Chi2 p % 
Risk 0.79  0.55 to 1.14 0.79 15 1.18 0.28 39.7 
Injury 1.15  0.83 to 1.59 0.40 0 0.41 0.52 11.7 
Failure 1.19  0.83 to 1.72 0.35 9 1.10 0.29 25.3 
Loss 0.88  0.35 to 2.24 0.79 0 0.58 0.44 3.7 
End stage 
kidney 
disease 
1.01  0.06 to 16.10 0.99 NA NA NA 1.1 
 
NA (not applicable) as there were no events in the CRYSTMAS[26] study.  
 
 
 
Table 4b. Meta-analysis (random effects model) characteristics of acute kidney injury 
severity and clinical outcome as defined by the RIFLE criteria.[29] CHEST[3] trial 
data relates all patients enrolled in to sepsis and non-sepsis groups, thus is included 
for illustrative purposes. Assessment was based on creatinine alone. The observed 
power (at 95% CI) for each component was calculated. 
 
RIFLE 
criteria 
Effect size measure Statistical heterogeneity Power 
RR 95% CI p I2 Chi2 p % 
Risk 0.96  0.68 to 1.35 0.81 68 6.27 0.04 18.1 
Injury 1.26 1.07 to 1.47 0.005 0 0.78 0.68 78.0 
Failure 1.27 1.04 to 1.55 0.02 0 1.25 0.54 60.3 
Loss 0.88  0.35 to 2.24 0.79 0 0.58 0.44 3.7 
End stage 
kidney 
disease 
1.01  0.06 to 16.10 0.99 NA NA NA 1.1 
 
NA (not applicable) as there were no events in the CRYSTMAS[26] study. 	  
